Kirkland, Canada

Denis Garceau

USPTO Granted Patents = 2 


Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Denis Garceau: Innovator in Pharmaceutical Formulations

Introduction

Denis Garceau is a notable inventor based in Kirkland, CA. He has made significant contributions to the field of pharmaceutical formulations, particularly in the area of amyloid inhibiting compounds. With a total of 2 patents, Garceau's work focuses on therapeutic methods for preventing and treating amyloidosis and related diseases.

Latest Patents

Garceau's latest patents include innovative formulations aimed at addressing amyloid deposition in subjects. The first patent describes therapeutic formulations and methods for inhibiting amyloid deposition, regardless of the clinical setting. The second patent outlines methods, formulations, and compositions specifically designed for the treatment of amyloidosis. These advancements highlight his commitment to improving health outcomes for individuals affected by amyloid-related diseases.

Career Highlights

Throughout his career, Garceau has worked with various companies, including BHI Limited Partnership and Kiacta Sarl. His experience in these organizations has allowed him to develop and refine his expertise in pharmaceutical innovations.

Collaborations

Garceau has collaborated with notable colleagues, including Julie Laurin and Wendy Hauck. These partnerships have contributed to the advancement of his research and the successful development of his patented formulations.

Conclusion

Denis Garceau's contributions to pharmaceutical formulations demonstrate his dedication to addressing critical health issues. His innovative patents and collaborative efforts position him as a key figure in the field of amyloid-related therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…